{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:32:36Z","timestamp":1760783556447},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[1999,10]]},"abstract":"<jats:p>\n            <jats:italic>Abstract<\/jats:italic>\n            \u2014Mibefradil and amlodipine are calcium antagonists with different channel selectivities. Mibefradil blocks both L- and T-type calcium channels; although in the usual pharmacological doses, it predominantly blocks the T-type channels. In contrast, amlodipine selectively blocks L-type channels. The goal of the present study was to assess whether this differential selectivity would result in different effects on end-organ damage in experimental hypertension. For this purpose, deoxycorticosterone acetate (DOCA)\u2013salt hypertensive rats were treated either with equipotent doses of mibefradil or amlodipine (30 mg \u00b7 kg\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 d\n            <jats:sup>\u22121<\/jats:sup>\n            as food admix). Despite the fact that both drugs decreased systolic arterial pressure to the same extent (140\u00b15 mm Hg in the mibefradil group and 144\u00b13 mm Hg in the amlodipine group versus 225\u00b15 mm Hg in the untreated-DOCA group), only mibefradil decreased proteinuria (35.5\u00b16.5 versus 103.3\u00b114.1 mg\/24 h in untreated DOCA-salt animals) and prevented glomerular lesions. Both drugs, however, prevented the occurrence of vascular renal lesions. To elucidate the mechanism responsible for this difference, we evaluated in an additional series of experiments the effects of mibefradil and amlodipine on plasma and renal renin concentrations, as well as the effects of the addition of enalapril, an ACE inhibitor, given on top of both drugs on proteinuria. Amlodipine, in contrast to mibefradil, markedly stimulated the plasma (17.8\u00b12.6 ng Ang I \u00b7 mL\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 h\n            <jats:sup>\u22121<\/jats:sup>\n            in the amlodipine group versus 3.9\u00b10.4 ng Ang I \u00b7 mL\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 h\n            <jats:sup>\u22121<\/jats:sup>\n            in the mibefradil group and 3.2\u00b10.3 ng Ang I \u00b7 mL\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 h\n            <jats:sup>\u22121<\/jats:sup>\n            in the untreated-DOCA group) and renal (2.42\u00b10.37 ng Ang I \u00b7 mL\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 h\n            <jats:sup>\u22121<\/jats:sup>\n            in the amlodipine group versus 0.36\u00b10.04 ng Ang I \u00b7 mL\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 h\n            <jats:sup>\u22121<\/jats:sup>\n            in the mibefradil group and 0.26\u00b10.08 ng Ang I \u00b7 mL\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 h\n            <jats:sup>\u22121<\/jats:sup>\n            in the untreated-DOCA group) renin concentrations. Stimulation of the renin-angiotensin system could explain the absence of a renal protective effect of amlodipine. This was also suggested by the fact that enalapril given in addition to amlodipine could decrease proteinuria. In conclusion, T-type channel blockade by mibefradil decreases blood pressure without stimulation of the renin-angiotensin system and therefore prevents most of the glomerular damage in DOCA hypertensive rats.\n          <\/jats:p>","DOI":"10.1161\/01.hyp.34.4.673","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:53:46Z","timestamp":1339462426000},"page":"673-678","update-policy":"http:\/\/dx.doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Contrasting Effects of Selective T- and L-Type Calcium Channel Blockade on Glomerular Damage in DOCA Hypertensive Rats"],"prefix":"10.1161","volume":"34","author":[{"given":"Habib","family":"Karam","sequence":"first","affiliation":[{"name":"From INSERM U367 (H.K., M-F.G., J.M.), Paris, France; ACTELION Ltd (J-P.C.), Allschwil, Switzerland; and INSERM U430, Ho\u0302pital Broussais (P.B.), Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Clozel","sequence":"additional","affiliation":[{"name":"From INSERM U367 (H.K., M-F.G., J.M.), Paris, France; ACTELION Ltd (J-P.C.), Allschwil, Switzerland; and INSERM U430, Ho\u0302pital Broussais (P.B.), Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Bruneval","sequence":"additional","affiliation":[{"name":"From INSERM U367 (H.K., M-F.G., J.M.), Paris, France; ACTELION Ltd (J-P.C.), Allschwil, Switzerland; and INSERM U430, Ho\u0302pital Broussais (P.B.), Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Franc\u0327oise","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"From INSERM U367 (H.K., M-F.G., J.M.), Paris, France; ACTELION Ltd (J-P.C.), Allschwil, Switzerland; and INSERM U430, Ho\u0302pital Broussais (P.B.), Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe\u0308l","family":"Me\u0301nard","sequence":"additional","affiliation":[{"name":"From INSERM U367 (H.K., M-F.G., J.M.), Paris, France; ACTELION Ltd (J-P.C.), Allschwil, Switzerland; and INSERM U430, Ho\u0302pital Broussais (P.B.), Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.27.3.426"},{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"M\u00e9nard J Karam H V\u00e9niant M Heudes D Bruneval P Clozel J-P. Effects of calcium blockade on end-organ damage in experimental hypertension. J Hypertens. 1997;15(suppl 3):S19\u2013S30.","DOI":"10.1097\/00004872-199715033-00004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.27.2.245"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701861"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-90-2-422"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.1991.tb00539.x"},{"key":"e_1_3_2_7_2","first-page":"S55","volume":"18","year":"1991","unstructured":"V\u00e9niant M, Clozel JP, Hess P, Wolfgang R. Hemodynamic profile of Ro 40\u20135967 in conscious rats: comparison with diltiazem, verapamil and amlodipine. J Cardiovasc Pharmacol. 1991;18:S55\u2013S58.","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.75.1.8013072"},{"key":"e_1_3_2_9_2","first-page":"88","volume":"49","year":"1943","unstructured":"Selye H, Hall CE, Rowley EM. Malignant hypertension produced by treatment with deoxycorticosterone acetate and sodium chloride. Can Med Assoc J. 1943;49:88\u201392.","journal-title":"Can Med Assoc J"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1986.251.4.C563"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Ueno Y Mohara O Brosnihan KB Ferrario CM. Characteristics of hormonal and neurogenic mechanisms of deoxycorticosterone-induced hypertension. Hypertension. 1988;11(suppl 1):I172\u2013I177.","DOI":"10.1161\/01.HYP.11.2_Pt_2.I172"},{"key":"e_1_3_2_12_2","first-page":"300","volume":"63","year":"1975","unstructured":"Gavras H, Brunner HR, Laragh JH, Vaughan ED, Koss M, Cote LJ, Gavras I. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess. Circ Res. 1975;63:300\u2013309.","journal-title":"Circ Res"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1987.57"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(95)00201-4"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000167540"},{"key":"e_1_3_2_16_2","first-page":"39","volume":"31","year":"1990","unstructured":"Osswald H, Weinheimer G, Kapp JF. Renal actions of calcium channel antagonists. J Neural Transm Suppl. 1990;31:39\u201353.","journal-title":"J Neural Transm Suppl"},{"key":"e_1_3_2_17_2","first-page":"115","volume":"5","year":"1991","unstructured":"Cappucio FP, Markandu ND, Sagnella GA, Singer DR, Buckley MG, Miller MA, MacGregor GA. Effects of amlodipine on urinary sodium excretion, renin-angiotensin-aldosterone system, atrial peptide and blood pressure in essential hypertension. J Hum Hypertens. 1991;5:115\u2013119.","journal-title":"J Hum Hypertens"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15735.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.88.6.8252698"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.1994.1098"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.67.6.1700933"},{"key":"e_1_3_2_22_2","first-page":"46","volume":"431","year":"1996","unstructured":"Scholz H, Kurtz A. Differential regulation of cytosolic calcium between afferent arteriolar smooth muscle cells from mouse kidney. Pfl\u00fcgers Arch. 1996;431:46\u201351.","journal-title":"Pfl\u00fcgers Arch"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1986.250.6.R960"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.83.1.103"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1990.70.4.1067"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.HYP.34.4.673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T17:25:54Z","timestamp":1715534754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.HYP.34.4.673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["10.1161\/01.HYP.34.4.673"],"URL":"https:\/\/doi.org\/10.1161\/01.hyp.34.4.673","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10]]},"assertion":[{"value":"1998-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-06-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}